Stay updated on Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.

Latest updates to the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedSite revision updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check41 days agoChange DetectedFooter revision updated from Revision: v3.4.2 to Revision: v3.4.3.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision updated to v3.4.2 and the prior funding/operating-status notice was removed; these are site-wide housekeeping changes rather than updates to study details.SummaryDifference0.4%

- Check76 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the system revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange DetectedAdded: Show glossary toggle; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0. Deleted: Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.